Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
PA Media on MSN10h
Novo Nordisk reprimanded for allegedly failing to disclose paymentsThe manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...
Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...
And that sounds to me like Novo Nordisk may have just discovered two new revenue streams it can extract from Ozempic. While not super cheap today, at 26 times trailing earnings and with growth ...
The Danish pharma giant, known for its blockbuster diabetes and weight-loss medications Ozempic and Wegovy, is on track to have its worst week on Wall Street this year. Novo Nordisk shares have ...
Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results